Balchem Corporation · NASDAQ:BCPC

Balchem — Investor Presentation (May 2014)

30 slides from Balchem's investor presentation, May 2014

  1. Slide 1: May 2014

    = bu Ze ro) — < co st a je) N ss J =

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains “forward-looking statements” within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s reasonable expectations and assumptions as of the date of this prese

  3. Slide 3: Balchem Corporation

    Balchem Corporation  Founded in 1967, Balchem is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical and medical sterilization industries  NASDAQ: BCPC  Headquarters: New Hampton, NY  Manufacturin

  4. Slide 4: Balchem at a Glance

    Balchem at a Glance Technology-driven, food and beverage solutions company developing complete systems, including ingredients and flavorings, to finished products 4

  5. Slide 5: Historical Consolidated Results (In millions)

    Historical Consolidated Results (In millions) Net Revenue 2013 $337M $400 $337 $292 $310 14% $300 $255 $82 15% $200 $88 $83 71% $100 $85 $86 $0 Animal Nutrition and Health 2010 2011 2012 2013 2014 YTD ARC Specialty Products Food, Pharma and Nutrition 5

  6. Slide 6: Historical Consolidated Results (In millions)

    Historical Consolidated Results (In millions) Net Earnings Fully Diluted Earnings Per Common Share $60 $1.45 $50 $45 $1.50 $1.32 $39 $40 $1.28 $0.35 $40 $33 $11 $1.12 $30 $1.00 $0.36 $12 $20 $0.38 $12 $0.50 $10 $0.36 $11 $9 $0.291 $0 $0.00 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 YTD 1 Refl

  7. Slide 7: Nutritional Products

    Nutritional Products  Nutritional products for ruminants, predominately dairy cows, to boost health and milk production.  Feed grade choline chloride - an essential nutrient for the poultry and swine industries. Industrial Products  Choline chloride and derivatives of choline chloride for numerou

  8. Slide 8: Animal Nutrition and Health

    Animal Nutrition and Health Highlights 2012 2013 2014 YTD Sales $216.3 MM $238.5 MM $61.1 MM Op. Income $28.1 MM $34.1 MM $7.3 MM  Targeting monogastric and ruminant production.  Growing sales into industrial applications, particularly Oil & Gas fracking Operational Excellence  #1 supplier global

  9. Slide 9: ANH Division Platforms

    ANH Division Platforms 2014 TTM Revenue - $239 million Protected Ingredients Base Ingredients (Shure™ Technology) ($45 MM; 19% of ANH) ($194 MM; 81% of ANH) Choline Industrial Ruminant Ruminant Chelated Feed Products Health Protein Minerals ($111 MM; ($83 MM; 46% of ANH) 35% of ANH) Nutritional Prod

  10. Slide 10: Animal Nutrition and Health

    Animal Nutrition and Health ($ in millions) ($ in millions) Revenue Operating Income $250 $239 $40 $216 $34.1 $201 $200 $32 $28.1 $171 $26.5 $24.1 $150 $24 $100 $16 $61 $7.3 $50 $8 $0 $0 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 YTD YTD 10

  11. Slide 11: Growing Industrial Opportunities

    Growing Industrial Opportunities 2014 TTM ANH Revenue - $239 MM 2014 TTM Industrial Revenue - $83 MM Current Industrial Products • Methylamines Feed Grade Choline 35% • Metam Sodium 46% Specialty Animal Nutrition and • Choline and choline Health Products derivatives for oil and gas 19% Industrial Gr

  12. Slide 12: Growth Market For Balchem

    Growth Market For Balchem  Horizontal drilling and multi-stage fracturing  Potassium chloride (KCL) is commonly used in preventing the swelling of clay as a temporary clay stabilizer, but carries environmental concerns  Choline chloride and choline bicarbonate offer an attractive, effective and m

  13. Slide 13: Balchem/Taminco Joint Venture

    Balchem/Taminco Joint Venture • Jointly expanding choline chloride production capacity • Supporting future growth of choline particularly for natural gas fracking in North America • Expected to be commissioned in second half of 2015 • Secured long term supply of critical raw material – TMA 13

  14. Slide 14: 14

    14

  15. Slide 15: ARC Specialty Products

    ARC Specialty Products Highlights 2012 2013 2014 YTD Sales $50.0 MM $51.1 MM $12.8 MM Op. Income $20.3 MM $20.2 MM $4.8 MM  GDP revenue growth Operational Excellence  Top provider of specialty gases  Top standards for safety, packaging, distribution  Manage customer inventory with just-in-time d

  16. Slide 16: ARC Specialty Products

    ARC Specialty Products ($ in millions) ($ in millions) Revenue Operating Income $60 $25 $50 $51 $20.3 $20.2 $48 $48 $20 $18.6 $42 $15.9 $36 $15 $24 $10 $13 $4.8 $12 $5 $0 $0 2010 2011 2012 2013 2014 YTD 2010 2011 2012 2013 2014 YTD 16

  17. Slide 17: Medical Device Market

    Medical Device Market  Overall medical device market Sterilization by Method continues to grow with aging demographics Other 1%  Ethylene Oxide utilization has Steam historically increased 2%-3% per 2% year  ARC has the resources to Radiation 40% Ethylene repackage hazardous chemicals Oxide safel

  18. Slide 18: Introducing: SensoryEffects

    Introducing: QSensorytffects’ + BALCHEM ENCAPSULATES

  19. Slide 19: Food, Pharma and Nutrition

    Food, Pharma and Nutrition Highlights 2012 2013 2014 YTD Sales $44.1 MM $47.6 MM $12.2 MM Op. Income $11.3 MM $11.2 MM $2.6 MM  Human grade choline positioned for double digit revenue growth Operational Excellence  Premier specialty ingredient business utilizing microencapsulation and application

  20. Slide 20: FPN Division Platforms

    FPN Division Platforms (Pre-Acquisition) ($ in millions) ($ in millions) Revenue Operating Income $60 $15 $48 $11.3 $48 $44 $12 $11.1 $11.2 $42 $43 $9.7 $36 $9 $24 $6 $12 $2.6 $12 $3 $0 $0 2010 2011 2012 2013 2014 YTD 2010 2011 2012 2013 2014 YTD Protected Food Ingredients Choline Ingredients ($27 M

  21. Slide 21: SensoryEffects Acquisition

    SensoryEffects Acquisition • Announced on March 31, 2014, Balchem completed the acquisition on May 7, 2014. SensoryEffects is a supplier of customized food and beverage ingredient systems, headquartered in St. Louis, Missouri. • SensoryEffects was a privately held entity, founded in 2005 by Charles

  22. Slide 22: Transaction Rationale

    Transaction Rationale  SensoryEffects provides customized, technology-driven food and beverage solutions including ingredients, bases and finished food systems for leading multinational and emerging high-growth food and beverage customers  The acquisition of SensoryEffects accelerates Balchem’s (a

  23. Slide 23: Strategic Rationale of the Acquisition

    Strategic Rationale of the Acquisition ■ Expand SensoryEffects business model domestically and internationally Significant Growth ■ Ability to cross-sell and penetrate the enhanced customer base Opportunities ■ Leverage SensoryEffects’ technique on selling a larger bundle product ■ Potential to leve

  24. Slide 24: Business Segments

    Business Segments ■ Customized wet- and dry- ■ Specialty spray-dried emulsified ■ Customized manufacturing of based flavor systems powders and formulated dry- cereal based systems blended systems ■ Chocolate systems ■ Specialty non-dairy and dairy ■ Ready-to-eat cereals ■ Juice and other drink bases

  25. Slide 25: Efficient Manufacturing

    Efficient Manufacturing SensoryEffects’ Asset Base Characterized By: ■ Production equipment designed for shorter runs with fast change-over times and processes ■ Ability to do longer runs to enhance efficiency and plant utilizations as desired ■ Suitable for customized products including organic, gl

  26. Slide 26: Pro-Forma Results (In millions)

    Pro-Forma Results (In millions) Net Revenue 2013 Pro-Forma Revenue $585M $800 SensoryEffects Balchem $585 $600 27% $475 $248 $400 $165 50% 14% $147 9% $200 $337 $310 $61 Animal Nutrition and Health $86 $0 Industrial 2012 2013 2014 YTD ARC Specialty Products Pro-Forma Food, Pharma and Nutrition 26

  27. Slide 27: Nutrient Applications

    NUTRIENT APPLICATIONS Benefits of VitaCholine  Continually builds and rebuilds cell health  Facilitates nervous systems function and communication  Helps maintain proper metabolic balance on the cellular level  Helps controls the deposition of fat  Develops the memory center of the brain in inf

  28. Slide 28: Choline – Anticipated RDI Designation

    Choline – Anticipated RDI Designation  In March, the FDA proposed an RDI for choline  The RDI of 550mg was part of a proposed labeling rule  The proposed rule could be final as early as H1 2015  Recognition of the high incidence of choline deficiency at 90%  Currently in comment period until Ju

  29. Slide 29: Public Recognition

    Public Recognition Nov. 1996 Forbes 200 Best Small Companies #193 Jun 2008 Balchem named to S&P 600 Nov. 1997 Forbes 200 Best Small Companies #116 Jul 2008 Fortune Small Business 100 Fastest Growing Companies #60 Oct. 2001 Forbes 200 Best Small Companies #128 Oct. 2008 Forbes 200 Best Small Companie

  30. Slide 30: Future

    Future  Positioned for growth  Organic  Acquisitions / JV’s / Partnerships  Highly skilled management team in place  Focusing research efforts  Building Global Animal Nutrition and Health Business  Food, Pharma and Nutrition is a growth engine  Stability of ARC Specialty Products  Strong ba

Balchem — Investor Presentation (May 2014) on 6ix